David Ishola

Prevention of Ebola virus disease through vaccination: where we are in 2018

Yves Lévy, Clifford Lane, Peter Piot et al. · The Lancet · 2018 · 125 citations · Full text

Medicine, Infectious Diseases, Preventive Medicine +12

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

David Ishola, Daniela Manno, Muhammed O. Afolabi et al. · The Lancet Infectious Diseases · 2021 · 95 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Muhammed O. Afolabi, David Ishola, Daniela Manno et al. · The Lancet Infectious Diseases · 2021 · 93 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Albumin-bound fatty acids induce mitochondrial oxidant stress and impair antioxidant responses in proximal tubular cells

David Ishola, Jan A. Post, Mirjan M. van Timmeren et al. · Kidney International · 2006 · 71 citations · Full text

Life Sciences, Biochemistry, Physiology +17

In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent

David Ishola, Dionne M. van der Giezen, Brunhilde Hähnel et al. · Nephrology Dialysis Transplantation · 2005 · 68 citations · Full text

Medicine, Nephrology, Pathobiology +10